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Abstract. Free norepinephrine and epinephrine were measured in two consecutive 
12-hour urine collections gathered during normal activity and sleep from 23 
panic-anxiety patients and 9 normal subjects. Mitral value prolapse (MVP) was 
found in 7 of 20 patients who had echocardiograms. Mean nighttime nor- 
epinephrine and epinephrine excretion in panic-anxiety patients without MVP was 
significantly higher than that of control subjects, and was significantly higher than 
that of anxiety patients with MVP. In the daytime, all groups had higher 
catecholamine (CA) levels, but the differences between the groups were less 
pronounced. Medication significantly relieved symptoms and was associated with 
decreased CA levels. Elevated basal CA levels may characterize the subgroup of 
panic-anxiety patients who do not have MVP. 
Key Words. Panic, anxiety, mitral valve prolapse, urine, epinephrine, 
norepinephrine, humans. 
Urinary and plasma catecholamine (CA) elevations in normal subjects during stress 
and anxiety have been well documented (Cannon, 19 15; Frankenhauser, 197 I ; Lader, 
1974; Redmond, 1979; Usdin et al., 1980; Ward et al., 1983; Nesse et al., in press). 
There have, however, been relatively few studies of CA levels in patients with anxiety 
disorders (Lader, 1978). This paucity of studies is surprising in view of the likelihood 
that CAs are mediators of anxiety symptoms, and the possibility that elevated CAs 
characterize some anxiety disorders. 
Several studies report correlations between CA levels and anxiety in patients with 
depression. In I3 drug-free patients with depression, elevated plasma CA levels were 
strongly correlated with anxiety ratings (r= 0.69,~ < O.Ol), but were weakly correlated 
with depression ratings (r = 0.261) (Wyatt et al., 1971). In another study of patients 
with anxiety and depression, red blood cell (RBC) catechol-O-methyltransferase 
(COMT) levels were above the normal range only in the patients who had mainly 
anxiety symptoms (Shulman et al., 1978). 
Randolph M. Nesse. M.D., is Assistant Professor, OliverG. Cameron. M.D., Ph.D., is Assistant Professor, 
and George C. Curtis, M.D., is Professor, Department of Psychiatry, University of Michigan Medical 
Center. Andrew J. Buda, M.D.. is Assistant Professor, and Daisy S. McCann, Ph.D., is Associate Professor 
of Biological Chemistry, Department of Internal Medicine, University of Michigan. Marla Huber-Smith. 
B.A., is Research Associate, Wayne County General Hospital. Westland. MI. (Reprint requests to Dr. 
R.M. Nesse. Dept. of Psychiatry, University of Michigan Medical Center, Box 56, Ann Arbor, MI 48109, 
USA.) 
0165-1781/85/$03.30 0 1985 Elsevier Science Publishers B.V. (Biomedical Division) 
68 
Patients with generalized anxiety disorder have been reported to have plasma 
epinephrine and norepinephrine levels significantly higher than controls, but their 
RBC COMT levels were only slightly above those of controls (Mathew et al., 1980). 
The same group of researchers subsequently failed to confirm elevations of plasma CA 
in generalized anxiety patients, and suggested that the earlier work might have been in 
error because blood samples were drawn immediately following venipuncture 
(Mathew et al., 1982). Perhaps patients with generalized anxiety disorder have a 
greater CA response to venipuncture than do normals. Increased plasma 3-methoxy- 
4-hydroxyphenethyleneglycol (MHPG) has been significantly correlated with anxiety 
ratings in normals (Uhde et al., 1982) and in phobic-anxious patients (Ko et al., 1983) 
but comparisons of plasma MHPG levels in anxiety disorder patients and normals are 
not available. There is a trend for urinary MHPG excretion to be higher in patients 
with panic attacks when compared to normal controls (Sheehan et al., 1984). 
Patients with panic disorder have been reported to have elevated plasma levels of 
both epinephrine and norepinephrine (Nesse et al., 1984; Cameron et al., 1984) or of 
epinephrine only (Appleby et al., 1981). Patients who had a panic attack during a 
lactate infusion tended to have higher plasma epinephrine levels than other patients, 
after the infusion (Appleby et al., 198 1). In that study, pre-infusion epinephrine levels 
were reported to be equivalent in patients who did, and did not, develop panic attacks. 
A more recent report from the same group states that elevated baseline epinephrine 
was “the only variable that distinguished patients who went on to panic from those 
who did not” (Liebowitz et al., 1983). Ballenger et al. (1984) have reported significant 
elevations of plasma epinephrine and norepinephrine in 36 patients with agoraphobia 
as compared to 9 normal controls. The differences were more pronounced when 
subjects were lying than standing. The patients’ mean level of plasma norepinephrine 
was three times higher than that of the normals while lying down (Ballenger et al., 
1984). 
Patients with panic disorder have an increased prevalence of mitral valve prolapse 
(MVP) (Crowe et al., 1980). People with MVP have anxiety-like symptoms, elevated 
plasma CA levels (Boudoulas et al., 1980; DeCarvalho et al., 1979; Pasternac et al., 
1982; Gaffney et al., 1983) and elevated urinary CA excretion (Boudoulas et al., 1983). 
The present report considers the hypothesis that the elevated CA levels reported for 
panic patients are an indirect result of the increased prevalence of MVP in panic 
patients. Separate measurement of daytime and nighttime CA excretion rates also 
allows consideration of the possibility that group differences in CA excretion result 
from different daytime activity levels. 
Methods 
Subjects. Twenty-three patients with panic disorder or agoraphobia with panic attacks were 
compared to nine control subjects (see Table 1). The patients had requested treatment at the 
University of Michigan Anxiety Disorders Clinic. Diagnoses were made according to DSM-III 
criteria (American Psychiatric Association, 1980) after a clinical examination by a psychiatrist 
experienced in diagnosing anxiety disorders. The controls were recruited by newspaper 
advertisements. Their psychiatric examinations revealed no anxiety or other mental disorder. 
All subjects were physically healthy and were not taking medication. All but two subjects had 
been medication free for a month or more. One patient had taken 4 mg of diazepam and 4 mg of 
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trifluroperazine/ day, and another had taken I5 mg of diazepam and 40 mg of naldolol/ day, 
until 2 weeks before the study. 





w/o MVPl w/o ECHO1 
n (total = 32) 9 23 7 13 3 
Sex (M/F) 7/2 5/18 l/6 3110 l/2 
Mean age 
(years) 26.0 (5.21 32.0 (11.3) 35.6 (14.2) 29.1 (6.6) 3.60 (14.7) 
Mean age at 
onset (years) - 22.2 (10.9) 24.4 (14.2) 22.1 (9.5) 17.3 (10.21 
Mean duration 
of illness 
(years) 9.78 (9.68) 11.14 (9.72) 7.00 (7.15) 18.67 (16.26) 
Mean weight 
(kg) 76.0 (12.7) 64.6 (11.0) 60.7 (8.4) 64.9 (12.6) 72.7 (12.4) 
Mean height 
(cm) 176.3 (8.5) 165.9 (8.4) 163.6 (11.2) 166.3 (6.1) 169.3 (10.61 
PD = panic disorder; PD w/MVP = panic disorder with mitral valve prolapse; PD w/o MVP = panic disorder 
without mitral valve prolapse; PD w/o ECHO = panic disorder without echocardiogram; standard deviations 
given in parentheses. 
1. Subgroups of the All PD group. 
Urine Collections. Subjects received verbal and written instructions regarding the urine 
collection technique and schedule. They were instructed to follow their usual diet but to avoid 
all strenuous exercise, medication, and caffeinated and alcoholic beverages during the urine 
collection. Two consecutive 12-hour samples (7 a.m.-7 p.m.; 7 p.m.-7 a.m.) were collected in jugs 
containing 10 ml of 5% acetic acid. Within 24 hours of collection, urine samples were brought to 
the laboratory, where total volume was recorded and samples were labeled and frozen at -20°C. 
After 3-14 months of treatment with imipramine, alprazolam, or a P-blocker, 10 patients 
collected urine a second time according to the same protocol. Urine samples were excluded if 
total volume was less than 300 ml/ 12 hours or if creatinine content was less than 0.3 mg/ 12 
hours. 
Assay. Epinephrine and norepinephrine were assayed by our modification of a single isotope 
derivative radioenzymatic technique (McCann and Huber-Smith, 1984). This assay has an 
intra-assay coefficient of variation of 3.92%, and an inter-assay coefficient of variation of 10.7%. 
Mitral Valve Prolapse Evaluation. Twenty of the patients and three of the controls had a 
phonocardiogram, auscultation by a cardiologist, and two-dimensional and M-mode 
echocardiograms, to determine if MVP was present. The MVP evaluations were assessed 
independently by three cardiologists who were blind to the clinical diagnosis, and MVP was 
considered present only if at least two of the cardiologists agreed on that diagnosis, based on 
M-mode or two-dimensional echocardiographic data that were interpreted using standard 
criteria. On M-mode echocardiography, MVP was considered present if mid-systolic buckling 
or systolic hammocking of 2 mm posterior to the C-D point was observed (Markiewicz et al., 
1976). On two-dimensional echocardiogram, MVP was defined by specific criteria for the 
parasternal long-axis view (Gilbert et al., 1976) and for the apical four-chamber view 
(Morganroth et al., 1980). 
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SCL-SO. Subjects completed the Symptom Checklist 90-R (SCL-90) at the initial evaluation 
and again at the second urine collection. 
Data Analysis. Epinephrine and norepinephrine data were analyzed separately at each time of 
day. Analyses of variance (ANOVAs) with planned contrasts were used to compare the groups. 
Results 
Seven of the 20 patients who received echocardiograms (35%) had MVP. Of three 
control subjects who had echocardiograms, none had MVP. Estimates of the 
prevalence of MVP using the same criteria for women in the general population are in 
the range of 6% to 21% (Markiewicz et al., 1976; Rosenberg et al., 1983). 
Patients excreted more of each CA during daytime and at night, but the difference 
was significant only for nighttime norepinephrine @ <0.036). The 13 patients who did 
not have MVP excreted substantially more CA than either patients with MVP or 
normal controls (see Fig. 1 and Table 2). These differences were much more prominent 
Fig. 1. Urinary free norepinephrine and epinephrine 
DAYTIME NOREPINEPHRINE tpg/12 h) NIGHTTIME NOREPINEPHRINE (gg/12 hl 
DAYTIME EPINEPHRINE (/.ig/lZ hl NIGHTTIME EPINEPHRINE 1~9112 h) 
Significance levels refer to comparisons with normals, unless otherwise indicated. 
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Table 2. Mean (SD) urinary norepinephrine (pg/12 hours) 
n Day 
All PD 22 21.48 (11.43) 
PD WIMVP 7 19.28 (11.14) 
PD w/o MVP 12 22.35 (12.901 






All PD vs. all normals F = 3.12, p < 0.088 
PD w/MVP vs. normals F = 1.05 
PD w/o MVP vs. normals F = 3.36, p < 0.078 
PD w/MVP vs. PD w/o MVP F = 0.38 
F = 4.89, p < 0.036 
F = 0.33 
F = 12.27, p < 0.002 
F=7.43,,-1<0.011 
Mean (SD) urinary epinephrine (pg/12 hours) 
n Day 
All PD 22 8.54 (5.32) 
PD w/MVP 7 7.43 (5.10) 
PD w/o MVP 12 9.85 (5.80) 
All normals 9 7.09 (2.801 
Night 




All PD vs. all normals 
PD w/MVP vs. normals 
PD w/o MVP vs. normals 
PD w/MVP vs. PD w/o MVP 
F=O.lO 
F = 0.02 
F = 1.75 
F= 1.16 
F = 1.53 
F = 0.03 
F = 6.20, p < 0.019 
F = 4.75, P < 0.038 
See note to Table 1 for abbreviations 
at night. Patients without MVP had nighttime epinephrine excretion significantly 
greaterthan bothcontrols(F=6.19,p<O.O19)and patients with MVP(F=4.75,p< 
0.038). Patients without MVP had nighttime norepinephrine excretion that was 
significantly higher than both controls (F= 12.27,~ < 0.002) and patients with MVP 
(F= 7.43,~ < 0.011). In the daytime, the differences between patients with and without 
MVP were minimal, while the differences persisted between controls and patients 
without MVP. 
Nonparametric presentation of these data shows the consistency of the differences. 
For nighttime epinephrine, 18 of 23 patients (78%) had values greater than the median 
for controls, and 11 (48%) had values greater than the maximum for controls. Eleven 
of the 13 patients without MVP (85%) had values greater than the median for patients 
with MVP. For nighttime norepinephrine, 21 of 23 patients (91%) had levels greater 
than the median for controls, and 8 of 23 (35%) had levels greater than the maximum 
for controls. Ten of the 13 patients without MVP (77%) had levels greater than the 
median for patients with MVP. 
A two-way ANOVA was performed to consider the effect of time of day and its 
possible interaction with diagnosis. Norepinephrine excretion and epinephrine 
excretion were both significantly lower at night (F = 10.04, p < 0.004 and F q 8.38, 
p < 0.008, respectively), but there were no significant interactions between time of day 
and diagnosis. 
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After 3-14 months of medication, SCL-90 subscale scores had significantly 
decreased (see Table 3). Urinary free epinephrine and norepinephrine decreased after 
treatment, but the difference approached statistical significance only for nighttime 
norepinephrine excretion (F = 2.24, p < 0.056). CA levels decreased more during 
treatment for those patients without MVP than for those with MVP, but the small 
number of subjects precludes more formal comparison. 
The data were also analyzed with a two-way ANOVA (diagnosis by sex) with three 
covariates (age, weight, and height) and planned contrasts in order to consider the 
possibility that the results might be accounted for by group differences in sex, age, 
weight, or height. The effects of sex, of the sex by diagnosis interaction, and of the 
covariates were all insignificant @ < 0. lo), and significant differences found in the 
main analysis remained significant in this analysis. Although the difference is not 
statistically significant, it is of interest that patients without MVP, when compared to 
those with MVP, had an earlier age of onset (22.1 vs. 24.4 years) and a shorter duration 
of illness before seeking treatment (7.00 vs. 11.14 years), possibly reflecting greater 
severity of illness. At the time of evaluation, however, patients with MVP had higher 
SCL-90 anxiety scores than patients without MVP (3.1 vs. 2.6; t q 1.36, p < 0.19). 
Table 3. Mean values: Pretreatment vs. during treatment 
During 
Pretreatment treatment t D 
Daytime epinephrine in = 10) 8.05 
Nighttime epinephrine in = 9) 5.52 
Daytime norepinephrine (n = 10) 21.36 
Nighttime norepinephrine (n = 9) 15.54 
SCL anxiety (n = 8) 3.10 
SCL somatic in = 8) 2.10 
SCL phobic (n = 8) 2.60 
SCL obsessive-compulsive (n = 8) 1.75 
SCL deoression (n = 8) 2.35 
7.24 1.23 NS 
4.40 1.50 NS 
20.54 0.12 NS 
10.59 2.24 0.056 
1.52 3.20 0.015 
1.37 3.15 0.016 
1.53 2.76 0.028 
1.02 2.66 0.033 
1.27 2.97 0.021 
Discussion 
This study supports the increased prevalence of MVP reported for patients with panic 
anxiety, and it confirms prior reports of elevated CA levels in patients with panic 
disorder. Panic patients with MVP have free CA excretion rates generally similar to 
those of controls, while panic patients without MVP have CA excretion rates 
significantly greater than either normals or panic patients with MVP. These 
unexpected group differences .were more pronounced for norepinephrine than 
epinephrine. The present findings differ from some plasma studies in which 
epinephrine differences predominated, but are consistent with the other plasma 
studies (Ballenger et al., 1984). Urine studies of CA metabolites would augment the 
free CA results reported here. 
These results differ from prior reports of elevated plasma CAs in subjects who have 
MVP. The discrepancy could result from differences between urinary and plasma 
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CAs, or from differences between MVP subjects who do and do not have panic. It may 
be, however, that the failure to find a significant difference between normals and 
anxiety patients with MVP is a type I1 error resulting from small sample size. For both 
CAs, the differences between groups were larger at night. This suggests that the groups 
differ in basal CA secretion rates and that daytime activity differences between the 
groups do not account for the findings. Data are not available to consider the 
possibility that the groups differed in activity levels or posture at night. 
Patients in this study demonstrated substantial benefit from treatment with 
alprazolam or imipramine, but group sizes were too small to allow correlation of 
treatment response with pretreatment findings. The finding of decreased CA levels 
during prolonged treatment is at variance with some reports (Ballenger et al., 1984), 
but is consistent with the observation that imipramine treatment causes a rise in 
plasma CAs that peaks at about 14 weeks of treatment and then declines toward 
baseline (Cameron et al., 1984). A study of CA levels in successfully treated 
panic-anxiety patients who are off medication would help to differentiate drug effects 
from changes associated with symptomatic improvement. 
These results contradict the hypothesis that elevated CA levels in panic-anxiety 
patients are accounted for by the subgroup of patients with MVP, and suggest, 
instead, that the observed CA elevations result mainly from the subgroup of panic 
patients without MVP. If this difference in CA excretion between patients with MVP 
and without MVP is confirmed, it might provide an important clue to the existence 
and etiologies of two distinct subgroups of patients with panic. The number of subjects 
in this study is small, so no firm conclusion is yet justified, but studies of patients with 
panic attacks will need to consider the possibility that subgroups with and without 
MVP may differ on other variables, in addition to their rate of CA excretion. 
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